+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Cancer Therapies - Global Market Trajectory & Analytics

  • ID: 834980
  • Report
  • September 2020
  • Region: Global
  • 915 Pages
  • Global Industry Analysts, Inc


  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Eli Lilly and Company
  • Glaxosmithkline Plc
  • Novartis AG
  • MORE
The global market for Cancer Therapies is projected to reach US$220.5 billion by 2025, driven by the rise in cancer prevalence to epidemic proportions and the still ongoing search to find effective treatments for the disease. Despite decades of research costing billions of dollars, a cure for cancer still remains elusive. This fact when juxtaposed with the epidemic spread of cancer will result in the disease emerging into the single most difficult to tackle public healthcare burden in the coming years. The pressure is therefore intensifying to research and develop newer and more effective therapies and treatment options. The reason why cancer is complex is due to its ability to continuously evolve and undergo molecular, genetic changes that affect behavior and response of tumor cells. Cancer cells evolve myriad ways to sabotage, stymie and trick the immune system preventing it from recognizing cancer cells, making the disease more resilient, aggressive and deadly. This has profound implications for the progression of the disease despite interventional therapies. Also, there are over 100 types of known cancer types. In addition the genetic diversity of tumors especially intra-tumor genetic heterogeneity makes finding a cure a challenge which the medical community continues to grapple with. Although the Cancer Genome Atlas (TCGA) has increased understanding of the diversity of cancer types, the disease continues to elude a cure while continuing to stretch the boundaries of medical science and understanding. Significant research is still required to understand the vast diversity of tumor gene expression, mutations and drug sensitivities.

Against the backdrop of tumor diversity, the universal one size fits all therapy which is the current standard of care is primitive. Therapies like chemotherapy and radiation, although help increase survival rates are beset with side-effects as they act as sledgehammers that destroy even healthy dividing cells at the cellular level. There is an urgent need for developing newer ways to target cancer`s diversity and evolution. While a cure for cancer is unlikely, targeted therapies will witness huge gains for their better prognosis. Targeted therapies revolve around identifying major pathways responsible for the disease and its progression and administering specific drugs targeting these pathways. Targeted therapies have lower side effects and are more effective than conventional therapies. However, targeted therapy increases the risk of emergence of treatment-resistant phenotypes. As an antidote to this problem is the interest shed on combined therapy targeting, stem cell transplants, molecular targeted therapy, and nanotechnology. Will these emerging therapies offer new paradigms in cancer treatment in the future, is however a question which only time will answer. Nevertheless, new advancements being made infuse optimism. For instance, scientists are close to identifying the key molecule involved in cancer`s mix and match diversity and evolution. Dubbed as DHX8, the protein influences the fundamental process in a cell called alternative splicing`. Aberrations in alternative splicing are linked to cancer`s progression and drug resistance. Drugs targeting the DHX8 Gene can likely help us find the elusive chink in cancer`s biological armor allowing us to finally steal a march over this complex disease. An exciting future currently awaits cancer therapies through 2025 despite all the challenges involved. The United States and Europe represent large markets worldwide with a combined share of 68% of the market. China ranks as the fastest growing market with a CAGR of 11.2% over the analysis period supported by the massive strides taken by the country in developing affordable next-generation therapies. Aggressive reforms in drug regulations and approval mechanisms have helped China emerge into the second largest pharmaceutical industry worldwide.

Competitors identified in this market include, among others:
  • AbbVie, Inc.
  • Amgen, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca Plc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Glaxosmithkline Plc
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer, Inc.
  • Takeda Pharmaceutical Company Limited.
Note: Product cover images may vary from those shown


  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Eli Lilly and Company
  • Glaxosmithkline Plc
  • Novartis AG
  • MORE


  • Impact of Covid-19 and a Looming Global Recession
  • Cancer Therapies: An Outlook
  • Chemotherapy & Targeted Therapy Lead the Global Cancer Therapies Market
  • By Cancer Type
  • USA Leads the Cancer Therapies Market
  • Biotherapies to Drive Growth
  • Rise in Cancer Incidence & Access to Modern Therapeutics Foster Growth
  • Total Number of New Cancer Cases by Type: 2018
  • Total Number of Cancer Deaths by Type: 2018
  • Cancer Incidence by Region: 2018
  • Cancer Mortality by Region: 2018
  • Age-Standardized Incidence and Mortality Rates of All Cancers (per 100000 Population) by Region: 2018
  • Cancer Research Spending Continues to Witness Growth
  • Number of FDA-Approved Cancer Drugs: 2010-2018
  • Select Cancer Drug Approvals in 2019
  • Select Cancer Drug Approvals in 2018
  • Cancer Drug Pipeline to Change the Pharma Landscape
  • Increasing Share of Cancer Drugs as % Of Total Pharma Drug Pipeline: 2010-2019
  • Global Competitor Market Shares
  • Cancer Therapies Competitor Market Share Scenario Worldwide (in %): 2019
  • Select Leading Cancer Drugs Worldwide by Sales: 2018

  • Industry Focuses on New Approaches to Treat Cancer
  • Recent Advancements in Cancer Drug Discovery
  • A New Immunotherapy Technique that Improves Efficacy and Safety of Cancer Treatment Developed by an Institute for Molecular Engineering Research Team
  • Lymphoma Therapy Developed by BeiGene Secures US FDA Approval
  • New Linker Technology for Enhancing Stability of ADCs
  • Personalized Medicine Gains Importance
  • Companion Diagnostics Accelerate Role of Personalized Medicine in Cancer Care
  • North American Companion Diagnostics Market (2019)
  • European Companion Diagnostics Market by Disease Area (2019)
  • Innovations in Cancer Drug Delivery: Key Factor in Product Differentiation
  • Peptoid-based Nanotubes Allow Precise, Targeted Delivery of Cancer Drugs
  • Combination Therapy: A Double Whammy Success
  • Patent Expiries of Branded Drugs to Trigger Generic Competition
  • Patent Expiries of Major Biopharmaceutical Drugs in the US and Europe
  • Gene Therapy based Approaches Present Potential Weapon for Battle against Cancer
  • Development of Novel Drug Candidates and Potential Therapies
  • Non-Viral Gene Therapy to Expedite Cancer Research and Introduction of New Therapies
  • Rise in Patient Assistance Programs (PAPs)
  • Top Financial Concerns for Cancer Patients: Ranked In Order of Influence
  • Oral Oncolytic Abandonment Rate (in %) by Patient Out-of-Pocket Expenses
  • Growth Drivers and Restraints
  • Demographics & Lifestyles Raise the Risk of Cancer
  • Percentage Breakdown of New Cases for All Cancers by Gender (2019)
  • Percentage Breakdown of New Cases for Colon and Rectum Cancers by Gender (2019)
  • Percentage Breakdown of New Cases for Lung & Bronchus Cancers by Gender (2019)
  • Unmet Needs Leave Scope for Further Research and Development
  • Low Entry Barriers in Cancer Research Encourages Breakthrough Developments
  • Increasing Investments by National Health Authorities
  • NCI Funding for Cancer Research (2002, 2008, 2014 and 2020)
  • Improved Screening, Diagnosis & Patient Survival Rates Trigger Growth
  • Molecular Imaging of Cancer: Critical in Improving Patient Outcomes
  • Innovations, Improvements, and Approvals Propel Growth
  • Select Cancer Drug Approvals (2018 & 2019)
  • Emerging Challenges in Cancer Drug Development
  • Drug Failures Deter Prospects of New Therapies
  • High Prices of Targeted Therapies Act as a Speed Breaker
  • Estimated Average Monthly Cost of Select Leading Cancer Drugs in the US as of 2016
  • Cancer Drug Approval Processes Need to Become More Flexible for Encouraging Innovation
  • Limited Tumor Specificity and Toxicity
  • Complicated Treatment Protocols: A Major Stumbling Block in Patient Compliance
  • Reduced Smoking
  • Global Cigarette Consumption Per Capita by Select Countries for 1970 and 2018
  • Reimbursement Coverage Remains a Major Challenge
  • Increase in Multidrug Resistance
  • Stringent Regulations Delay Market Approval
  • Challenges Encountered in Clinical Trials
  • Overview of Cancer Therapy Segments
  • Immunotherapy: A Promising Segment
  • Global Cancer Immunotherapy Market by Therapy Type (in %) for 2019
  • Monoclonal Antibodies for Cancer Treatment
  • Monoclonal Antibodies in Late-Stage Clinical Trials for Cancer Treatment
  • Vaccines: A Promising Future Area of Cancer Therapeutics
  • Approved Therapeutic Cancer Vaccines Worldwide
  • CAR-T Therapy: An Innovative Therapy Focused on Engineering of Patients’ Immune Cells for Cancer Treatment
  • UK Researchers New Approach Holds Potential to Boost Immunotherapies
  • Targeted Therapy: An Overview
  • Types of Targeted Therapy
  • Chemotherapy: An Overview
  • Types of Chemotherapy
  • Risks Associated with Chemotherapy
  • Hormone Therapy
  • Drug Classes in Hormone Therapy
  • Prostate Cancer
  • Global Sales of Leading Prostate Cancer Drugs in US$ Million: 2018
  • Select General Risk Factors and their Relative Risk Rate in Prostate Cancer
  • Select FDA Approved Drugs for Palliative Treatment of Advanced Prostate Cancer
  • Select Drugs that Received Approval for Castration-Resistant Prostate Cancer (CRPC)
  • Prostate Cancer Phase IV Completed Clinical Trials with Results
  • Lung Cancer
  • Age-Standardized Lung Cancer Rates for Select Countries
  • Age-Standardized Lung Cancer Rates in Men for Select Countries
  • Age-Standardized Lung Cancer Rates in Women for Select Countries
  • Select FDA-Approved Non-Small Cell Lung Cancer Drugs
  • Select Phase IV Completed Clinical Trials with Results: As of Dec, 2019
  • Select Phase III Completed Clinical Trials with Results: As of December 30, 2019
  • Breast Cancer
  • Select FDA Approved Breast Cancer Drugs
  • Breast Cancer Phase IV Completed Clinical Trials with Results: As of Dec 30, 2019
  • Breast Cancer Select Phase III Completed Clinical Trials with Results: As of Dec 30, 2019
  • Renal Cancer
  • Select FDA-Approved Renal Cell Carcinoma Drugs
  • Cervical Cancer
  • Colorectal Cancer
  • Select FDA-Approved Colorectal Cancer Drugs
  • Skin Cancer
  • Pancreatic Cancer
  • Non-Hodgkin’s Lymphoma
  • Leukemia
  • Standard Approved Mode of Therapy for AML by Age Group
  • Blood Cancer Phase IV Completed Clinical Trials with Results: As of Dec 30, 2019
  • Blood Cancer Phase III Completed Clinical Trials with Results: As of Dec 30, 2019
  • Bladder Cancer
  • Endometrial Cancer



  • Market Overview
  • Rising Cancer Cases Spur Growth in Anti-Cancer Drugs Market
  • Estimated Number of New Cancer Cases and Deaths in the US (2019)
  • Number of Cancer Drugs in Development for the Years 2006, 2009, 2012, 2015 and 2018
  • Number of FDA-Approved Oncology Drugs in the US (2010-2018)
  • Cancer Drugs as % of Drug Pipeline in the US for the Period 2010-2019
  • Patient Assistance Programs Alleviate Cost Burden of Patients to Some Extent
  • Personalized Medicine Gathers Momentum for Cancer Treatment in the US
  • A Surging US Prostate Cancer Therapeutics Market
  • Medicaid Reimbursement Rates for Cancer Treatment with Radiation Indicate Notable Disparity among States
  • Oncology Care Model to Improve Quality and Reduce Financial Toxicity of Cancer Care
  • CMS Hikes Reimbursement Rate for CAR-T Therapy
  • Market Analytics
  • Number of New Cancer Cases in Canada: 2019
  • Market Analytics

  • Cancer Therapies Market: Overview
  • Number of New Cancer Cases Diagnosed (in Thousands) in China: 2018
  • Chinese Drug Makers Look to Strengthen Domestic Presence with Low-cost Products
  • Market Analytics
  • Rising Cancer Incidence and New Drug Development Augur Well for European Cancer Therapies Market
  • Cancer Incidence in Europe: Number of New Cancer Cases (in Thousands) by Site for 2018
  • Number of New Cancer Cases Diagnosed (in Thousands) in the UK: 2018
  • Market Analytics







  • An Insight into Asia-Pacific Market for Cancer Therapies
  • Cancer Incidence in Asia: Number of New Cancer Cases (in Thousands) for 2019
  • Market Analytics
















  • Total Companies Profiled: 75
Note: Product cover images may vary from those shown
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Glaxosmithkline Plc
  • Johnson & Johnson Services Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited.
Note: Product cover images may vary from those shown